Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
Nat Commun. 2024 Jan 3;15(1):225.
doi: 10.1038/s41467-023-44575-3.
1 Weill Cornell Medicine, Department of Cardiothoracic Surgery, New York, New York, USA. nkaltork@med.cornell.edu.
2 Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, New York, New York, USA.
3 Weill Cornell Medicine, Department of Cardiothoracic Surgery, New York, New York, USA.
4 Department of Population Health Sciences, Weill Cornell Medicine, New York, New York, USA.
5 Weill Cornell Medicine, Division of Hematology and Oncology, New York, New York, USA.
6 Weill Cornell Medicine, Caryl and Israel Englander Institute for Precision Medicine, Institute for Computational Biomedicine, Department of Physiology and Biophysics, New York, New York, USA.
7 Weill Cornell Medicine, Department of Radiation Oncology, New York, New York, USA.
8 Department of Pathology, Northwell Health, Greenvale, New York, New York, USA.
9 Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, Vagelos College of Physicians & Surgeons, New York, New York, USA. bi2175@cumc.columbia.edu.
10 Department of Systems Biology, Program for Mathematical Genomics, Columbia University, New York, New York, USA. bi2175@cumc.columbia.edu.
11 Columbia Center for Translational Immunology, New York, New York, USA. bi2175@cumc.columbia.edu.
12 Weill Cornell Medicine, Department of Biochemistry, New York, New York, USA. temcgraw@med.cornell.edu.